IDEAYA to present Phase 2/3 uveal melanoma trial data at ASCO 2026

April 21, 2026 10:15 AM

IDEAYA Biosciences Inc. (NASDAQ: IDYA) will present complete data from its Phase 2/3 registrational trial OptimUM-02 at the 2026 American ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found